Sterile, lab-raised green bottle fly larvae are used for maggot debridement therapy (MDT), most commonly for non-healing wounds, such as diabetic ulcers. Maggots promote healing by cleaning the wound, remove dead tissue, and secrete antimicrobial factors. The treatment is cost-effective and approved by the FDA. However, there is no evidence from randomized clinical trials that MDT shortens wound healing times.
Scientists at North Carolina State University have shown that genetically engineered green bottle fly (Lucilia sericata) larvae can produce and secrete a secrete human platelet-derived growth factor-BB (PDGF-BB), a molecule that helps promote cell growth and wound healing. The study is published online in BMC Biotechnology.With the goal of making a strain of maggots with enhanced wound-healing activity, scientists have used two techniques. The first utilized heat to trigger the production of PDGF-BB in transgenic green bottle flies. Although the human growth factor was detectable in certain structures within the larvae after the larvae were shocked with high heat (37°C), the PDGF-BB was not detectable in maggot excretions or secretions, making it unworthy of clinical use.
The second technique was more successful. Dr. Scott, the leading scientists behind this research and colleagues engineered the flies such that they only made PDGF-BB if raised on a diet that lacked the antibiotic tetracycline. PDGF-BB was made at high levels in the larvae and was found in the excretions and secretions of maggots, making the technique a potential candidate for clinical use.
According to Dr. Scott, they see this as »a proof-of-principle study for the future development of engineered L. sericata strains that express a variety of growth factors and anti-microbial peptides with the long-term aim of developing a cost-effective means for wound treatment that could save people from amputation and other harmful effects of diabetes.« This brings new hope to the vast majority of people with diabetes live in low- or middle-income countries and cannot afford expensive treatment options.
Jana Erjavec, PhD, BioSistemika LLC
Original article: GEN News
Featured image courtesy: By Calibas (Own work) [Public domain], via Wikimedia Commons